PT0253 Clinical Trials (2026): 1 Studies for Solid Tumor
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 PT0253 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Solid Tumor) and 115 total planned enrollment. 1 PT0253 clinical trial is actively recruiting at 7 U.S. sites across 5 states. Most recent activity: NCT06797336 (Jun 2027).
Where to Participate: All PT0253 Trial Sites in the U.S. (7 sites across 5 states)
Every actively recruiting PT0253trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| MA | Dana Farber/Massachusetts General Hospital, Inc | Boston02215 | NCT06797336 | Map |
| TN | SCRI Lake Mary | Nashville37203 | NCT06797336 | Map |
| TN | SCRI Oncology Partners | Nashville37203 | NCT06797336 | Map |
| TX | New Experimental Therapeutics of San Antonio LLC | San Antonio78229 | NCT06797336 | Map |
| TX | START - South Texas Accelerated Research Therapeutics, LLC | San Antonio78229 | NCT06797336 | Map |
| UT | START Mountain Region | West Valley City84119 | NCT06797336 | Map |
| VA | NEXT Virginia | Fairfax22031 | NCT06797336 | Map |
PT0253 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P1 | 1 | 1 |
Recruiting PT0253 clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT06797336 | A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors | P1 | Solid Tumor | 115 | Dec 2024 |
All PT0253 trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06797336 | A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors | P1 | recruiting | 115 | PAQ Therapeutics, Inc. | Dec 2024 |
PT0253 clinical trials: frequently asked questions
- How many PT0253 clinical trials are there?
- 1 PT0253 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are PT0253 clinical trials recruiting in 2026?
- Yes — 1 PT0253 trial is actively recruiting in 2026, with 7 U.S. sites across 5 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is PT0253 being studied for?
- PT0253 is being studied for Solid Tumor. The trials are grouped by indication on this page.
- What phase is PT0253 in?
- PT0253 clinical trials span 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors PT0253 clinical trials?
- The lead sponsor across the most PT0253 trials is PAQ Therapeutics, Inc.. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming PT0253as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: